Fair. I just had a look at the numbers. Is less clear when you drill down to individual countries and if you only look at the most virulent diseases, also with a lot of the funding, like the global fund for instance, many of the EC countries donate twice, once as part of their EC obligation, and again as a national donation, so you may miss a lot if you just look at EC funds. But you are definitely right overall, the US state spending seems massive in comparison.

Mind you, this got me thinking, if you were going to expect any of that to affect the pricing of essential drugs, you would expect it to push prices down in the US, given there is what amounts to the worlds largest drugs industry subsidy. Also, I notice that big pharma is not generally skint, so if there is a shortage of new drugs (is this actually true in general, or is it just truthiness?), I would agree with you that it is not down to a shortage of money.